Our proprietary cell characterization and manufacturing process is scalable, cost-effective and has already been reviewed by the FDA in two Pre-Investigational New Drug (IND) meetings
Q Therapeutics has developed a multi-step isolation and purification process that yields a rich population of Q-Cells®
(human glial-restricted progenitor cells). The core value proposition for our proprietary manufacturing process is our capability to cost-effectively produce a high-quality cellular therapeutic product with the economies of scale usually reserved for big pharma.
Each manufactured lot produces enough cells to treat hundreds of patients.